Update to Liquidia’s Participation in the Jefferies Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) has announced its participation in the Jefferies Healthcare Conference, where CFO Michael Kaseta will engage in a fireside chat on June 9, 2022, at 8:00 am ET. The conference runs from June 8 to 10, 2022, in New York City. Investors can access a live webcast of the event on Liquidia’s website, which will be archived for 30 days after the conference.
Liquidia focuses on developing products for pulmonary hypertension using its PRINT® Technology, including its inhalation powder YUTREPIA™ for treating pulmonary arterial hypertension.
Positive
- CFO Michael Kaseta's participation in a significant healthcare conference may enhance investor visibility.
- The webcast allows for wider accessibility, potentially increasing investor engagement.
Negative
- None.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was -1.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today an update to the company’s participation in the Jefferies Healthcare Conference. Mr. Michael Kaseta, Chief Financial Officer, will participate in a fireside chat on Thursday, June 9, 2022, now scheduled for 8:00 am Eastern Time. The conference is taking place June 8-10, 2022, in New York City.
A webcast of the event will be available on the investors section of Liquidia’s website at https://liquidia.com/investors/events-and-presentations, and will be archived for 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.